Objective
to report the 5-year clinical outcome of a biolimus-eluting (BES) versus everolimus-eluting (EES) stent implantation
Study
prospective, multicentre, randomised non-inferiority trial (margin hazard ratio 1.38)
Population
stable angina and unstable patients (17%)
Endpoints
any target vessel lesion revascularisation (TLR) and safety composite: death or MI
Conclusion
at 5 years the clinical outcome of a BES-stent is non-inferior to an EES-stent implantation
Natsuaki et al. EuroIntervention 2018;14:815-8